YCT-529 Oral Male Contraceptive
RARa Inhibitors, ER-50891
- User: Male
- Hormonal: Non-Hormonal
-
Delivery type:
- Oral
-
Intended Duration:
- Short-Acting
- Development Stage: Phase II
- Developer(s)/researcher(s): YourChoice Therapeutics, University of Minnesota
Details
- API: YCT-529 Free Acid - C29H25NO3
- Target: RAR-alpha
-
Mechanism of Action:
- Reduced Sperm Production
- Inactive Materials: Not Yet Determined
- Regimen: 1 Pill/Day
- MPT: Not Potential MPT
- Promising Attributes: YCT-529 is non-hormonal and anticipated to present a desirable side effect profile to end users.
Product Status
Active Clinical Development
History
2020: University of Minnesota affirms viability of RARa-targeting compounds for development as male contraceptive methods
2022: University of Minnesota announces at the American Chemical Society Spring 2022 conference that YCT-529 has been found to effectively lower sperm count without related toxicity in mice.
2023: University of Minnesota & YourChoice jointly announce initiation of Phase I clinical research in the UK to investigate the safety, tolerability, PK, and PD of single ascending oral doses of their drug candidate, YCT-529. YourChoice has engaged in extensive pre-clinical animal evaluation of YCT-529.
2024: YourChoice announces initiation of Phase Ib/IIa clinical research in New Zealand to investigate safety and tolerability of ascending oral doses of YCT-529.
2025: YourChoice publishes safety and pharmacokinetics results from Phase Ia clinical evaluation in 16 male volunteers. Single doses of up to 180mg YCT-529 are reported to have no effect on heart rate, hormone, sex hormone binding globulin or inflammatory biomarker levels, sexual desire, or mood. These results suggest further clinical evaluation would be safe and appropriate. As of 2026, Phase IIa evaluation is ongoing.
Evaluation of other potential RARa inhibiting compounds and refinement of YCT-529 is active at the University of Minnesota.